Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Tanaka

Showing results (341-350 of 349) with videos related to

Pageof 35
Sort By:
You have reached the last page of results.This site can display upto 349 results.
Cancer Medicine|May 22, 2023
Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small-cell lung cancer patientsYuka Oku, Gouji Toyokawa, Sho Wakasu, et al.
Archives of Gerontology and Geriatrics|January 1, 2019
Association between long-term care and chronic and lifestyle-related disease modified by social profiles in community-dwelling people aged 80 and 90; SONIC studyEri Kiyoshige, Mai Kabayama, Yasuyuki Gondo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2023
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung CancerPasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 StudyMyung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, et al.
JTO Clinical and Research Reports|April 27, 2026
Durvalumab Plus Chemotherapy in Patients With <i>EGFR</i>-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARDByoung Chul Cho, Makoto Nishio, Myung-Ju Ahn, et al.
International Journal of Clinical Oncology|May 4, 2019
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IVHiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2021
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort studyKentaro Ito, Takeharu Yamanaka, Hidetoshi Hayashi, et al.
JTO Clinical and Research Reports|September 30, 2021
Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With <i>EGFR</i> MutationsKiichiro Ninomiya, Shunsuke Teraoka, Yoshitaka Zenke, et al.
Environmental and Molecular Mutagenesis|September 13, 2011
International Pig-a gene mutation assay trial: evaluation of transferability across 14 laboratoriesStephen D Dertinger, Souk Phonethepswath, Pamela Weller, et al.
Pageof 35

Showing results (341-350 of 349) with videos related to

Sort By:
Pageof 35
You have reached the last page of results.This site can display upto 349 results.
Cancer Medicine|May 22, 2023
Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small-cell lung cancer patientsYuka Oku, Gouji Toyokawa, Sho Wakasu, et al.
Archives of Gerontology and Geriatrics|January 1, 2019
Association between long-term care and chronic and lifestyle-related disease modified by social profiles in community-dwelling people aged 80 and 90; SONIC studyEri Kiyoshige, Mai Kabayama, Yasuyuki Gondo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2023
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung CancerPasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 StudyMyung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, et al.
JTO Clinical and Research Reports|April 27, 2026
Durvalumab Plus Chemotherapy in Patients With <i>EGFR</i>-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARDByoung Chul Cho, Makoto Nishio, Myung-Ju Ahn, et al.
International Journal of Clinical Oncology|May 4, 2019
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IVHiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2021
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort studyKentaro Ito, Takeharu Yamanaka, Hidetoshi Hayashi, et al.
JTO Clinical and Research Reports|September 30, 2021
Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With <i>EGFR</i> MutationsKiichiro Ninomiya, Shunsuke Teraoka, Yoshitaka Zenke, et al.
Environmental and Molecular Mutagenesis|September 13, 2011
International Pig-a gene mutation assay trial: evaluation of transferability across 14 laboratoriesStephen D Dertinger, Souk Phonethepswath, Pamela Weller, et al.
Pageof 35